> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for BMS’s Opdivo
- URL: https://www.fdaweb.com/regulatory-review-period-for-bmss-opdivo/
- Published: 2016-12-02T12:00:00.000Z
- Updated: 2026-09-14T21:52:02.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5137473

*Federal Register* Notice: FDA has determined the regulatory review period for Bristol Myers Squibb’s lung cancer therapy Opdivo (nivolumab) for patent extension purposes is 3,071 days. Of this time, 2,925 days occurred during the testing phase, while 146 days occurred during the approval phase. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2016-12-02/pdf/2016-28917.pdf?ref=fdaweb.com).